mhurhangee/ep-ind-claims huggingface dataset:
A wheel unit for a rail vehicle having a nominal speed above 140 km/h, in particular, a high-speed rail vehicle, said wheel unit comprising a rim section, wherein - said rim section (106.1) defines a rolling axis (106.2) of said wheel 106, a rim width along said rolling axis (106.2) and a tread datum plane perpendicular to said rolling axis (106.2), - said rim section (106.1) has a sectional contour (106.3) in a sectional plane comprising said rolling axis (106.2), - said sectional contour (106.3) comprises a wheel profile section (106.4), - said wheel profile section (106.4) comprises a flange section and a tread section, - said tread section is configured to contact a rail of a track in a contact location during normal operation of said wheel unit; - said tread section, in an unworn or re-profiled state, comprises a non-cylindrical contour section; characterized in that - said tread section, in said unworn or re-profiled state, further comprises a cylindrical contour section; - said cylindrical contour section, along said rolling axis (106.2), has an inner end (106.5), an outer end (106.6) and a cylindrical contour width between said inner end (106.5) and said outer end (106.6); - said cylindrical contour section is located such that, along said rolling axis (106.2), one of said inner end (106.5) and said outer end (106.6) has an end distance from said tread datum plane which is at most 50% of said cylindrical contour width, said cylindrical contour section intersecting said tread datum plane. - said rim section (106.1) defines a rolling axis (106.2) of said wheel 106, a rim width along said rolling axis (106.2) and a tread datum plane perpendicular to said rolling axis (106.2), - said rim section (106.1) has a sectional contour (106.3) in a sectional plane comprising said rolling axis (106.2), - said sectional contour (106.3) comprises a wheel profile section (106.4), - said wheel profile section (106.4) comprises a flange section and a tread section, - said tread section is configured to contact a rail of a track in a contact location during normal operation of said wheel unit; - said tread section, in an unworn or re-profiled state, comprises a non-cylindrical contour section; - said tread section, in said unworn or re-profiled state, further comprises a cylindrical contour section; - said cylindrical contour section, along said rolling axis (106.2), has an inner end (106.5), an outer end (106.6) and a cylindrical contour width between said inner end (106.5) and said outer end (106.6); - said cylindrical contour section is located such that, along said rolling axis (106.2), one of said inner end (106.5) and said outer end (106.6) has an end distance from said tread datum plane which is at most 50% of said cylindrical contour width, said cylindrical contour section intersecting said tread datum plane.
Sound damping part for arrangement in a motor vehicle, comprising a sound damping element, in particular a foam element, for essentially flat contact with at least one region of a motor vehicle body, in particular an end wall, for the purpose of reducing sound transmission into a passenger compartment, wherein the sound damping part has at least one plug part connected to the sound damping element and having a plug for insertion into an opening of a body component or body component composite for the purpose of producing a non-positive and/or positive connection of the sound damping part to a material of the body component or body component composite, said material forming the opening, characterized in that the sound damping element and the plug part are connected to one another in an articulated manner.
An implantable drug delivery device for controlled drug delivery to the bladder or other genitourinary sites, comprising: a drug reservoir, the drug reservoir having an elongated shape, the drug reservoir formed from a deformable material; a drug loaded in the drug reservoir; characterized in that the implantable drug delivery device comprises: a first filament attached to a first end of the drug reservoir; a second filament attached to a second end of the drug reservoir; and a fastener positioned about the first and second filaments (120, 122), the fastener permitting shortening and preventing lengthening of the filaments (120, 122) with reference to the ends of the drug reservoir. a drug reservoir, the drug reservoir having an elongated shape, the drug reservoir formed from a deformable material; a drug loaded in the drug reservoir; a first filament attached to a first end of the drug reservoir; a second filament attached to a second end of the drug reservoir; and a fastener positioned about the first and second filaments (120, 122), the fastener permitting shortening and preventing lengthening of the filaments (120, 122) with reference to the ends of the drug reservoir.
Oxytherapy instrument for high flow oxygen therapy, presenting: - a nasal part comprising a gas channel for a patient's gas and two nasal cannulas being in fluid communication with the gas channel, each with a patient gas outlet opening, - at least one pressure regulating valve which is a silicone membrane into which at least two intersecting slots are introduced, by which at least four movable valve flaps are formed outwardly and inwardly, and - at least one preformed tube, having at least one gas channel which opens into a gas inlet opening and a gas outlet opening of the preformed tube, in which the preformed tube opens with its gas outlet opening into a gas inlet opening of the nasal part, and - the oxytherapy instrument has a gas distribution device intended to be connected to a patient gas source, in which the at least one preformed tube opens with its gas inlet opening into a gas outlet opening of the gas distribution device, - the preformed tube has a cross-sectional shape of its at least one gas channel which is in the shape of a star, flower, arc of a circle or polygon, and - the at least four valve flaps movable outwardly and inwardly of the at least one pressure regulating valve open in proportion to the differential pressure in the presence of a differential pressure between the pressure atmospheric and gas pressure in the gas distribution apparatus and / or the nasal part with a spring force inherent in the valve plug material. - a nasal part comprising a gas channel for a patient's gas and two nasal cannulas being in fluid communication with the gas channel, each with a patient gas outlet opening, - at least one pressure regulating valve which is a silicone membrane into which at least two intersecting slots are introduced, by which at least four movable valve flaps are formed outwardly and inwardly, and - at least one preformed tube, having at least one gas channel which opens into a gas inlet opening and a gas outlet opening of the preformed tube, in which the preformed tube opens with its gas outlet opening into a gas inlet opening of the nasal part, and - the oxytherapy instrument has a gas distribution device intended to be connected to a patient gas source, in which the at least one preformed tube opens with its gas inlet opening into a gas outlet opening of the gas distribution device, - the preformed tube has a cross-sectional shape of its at least one gas channel which is in the shape of a star, flower, arc of a circle or polygon, and - the at least four valve flaps movable outwardly and inwardly of the at least one pressure regulating valve open in proportion to the differential pressure in the presence of a differential pressure between the pressure atmospheric and gas pressure in the gas distribution apparatus and / or the nasal part with a spring force inherent in the valve plug material.
A crash safety battery compartment configured to receive a battery having a case, said battery compartment comprising: • an outer skin, • one or more elements (4, 5, 6, 7, 9, 10, 11, 12, 18, 19, 20) operating on the physical principle of a mechanical compression spring, wherein • the elements (4, 5, 6, 7, 9, 10, 11, 12, 18, 19, 20) are arranged so that one axis of one or more of the elements (4, 5, 6, 7, 9, 10, 11, 12, 18, 19, 20) is perpendicular to a corresponding axis of one or more of the elements, characterised in that the one or more elements (4, 5, 6, 7, 9, 10, 11, 12, 18, 19, 20) are positioned between the outer skin and a space for receiving a battery whereby the elements (4, 5, 6, 7, 9, 10, 11, 12, 18, 19, 20) hold a battery in place in a battery compartment having a double floor system comprising the battery case and the outer skin. • an outer skin, • one or more elements (4, 5, 6, 7, 9, 10, 11, 12, 18, 19, 20) operating on the physical principle of a mechanical compression spring, wherein • the elements (4, 5, 6, 7, 9, 10, 11, 12, 18, 19, 20) are arranged so that one axis of one or more of the elements (4, 5, 6, 7, 9, 10, 11, 12, 18, 19, 20) is perpendicular to a corresponding axis of one or more of the elements,
A capsule (6; 60) containing liquid for atomisation by an atomiser of an electronic smoking system, comprising: a controller (40; 80), which is responsive when mounted to an electronic smoking device to receive data from and to transmit data to control electronics of the electronic smoking device, via a communication device (50, 51, 52), the controller (40; 80) of the capsule (6; 60) being adapted to respond to a challenge response authentication from the control electronics when the capsule (6; 60) is mounted to the device, characterized in that, the controller (40; 80) is adapted to apply a predefined secret key to a random number provided by the control electronics, to add a hash key thereto, and to transmit the encrypted random number to the control electronics. a controller (40; 80), which is responsive when mounted to an electronic smoking device to receive data from and to transmit data to control electronics of the electronic smoking device, via a communication device (50, 51, 52), the controller (40; 80) of the capsule (6; 60) being adapted to respond to a challenge response authentication from the control electronics when the capsule (6; 60) is mounted to the device, characterized in that, the controller (40; 80) is adapted to apply a predefined secret key to a random number provided by the control electronics, to add a hash key thereto, and to transmit the encrypted random number to the control electronics.
A composition for use in a method of treating diabetes mellitus, wherein the composition comprises a combination of active ingredients, wherein the composition has an excellent hypoglycemic effect that suppresses lactic acidosis without substantially increasing the blood lactate concentration, wherein the composition comprises the active ingredients: a) branched-chain amino acids or derivatives of the branched-chain amino acids, and b) biguanide derivatives, or salts of the biguanide derivatives, wherein the biguanide derivatives are selected from the group consisting of metformin hydrochloride, phenformin and buformin, and wherein the disease to be treated is diabetes mellitus associated with renal dysfunction. wherein the composition comprises the active ingredients: a) branched-chain amino acids or derivatives of the branched-chain amino acids, and b) biguanide derivatives, or salts of the biguanide derivatives, a) branched-chain amino acids or derivatives of the branched-chain amino acids, and b) biguanide derivatives, or salts of the biguanide derivatives, wherein the biguanide derivatives are selected from the group consisting of metformin hydrochloride, phenformin and buformin, and wherein the disease to be treated is diabetes mellitus associated with renal dysfunction.
An organic electroluminescent device material, characterized in that the organic electroluminescent device material comprises a carborane compound represented by the general formula: in the general formula: a ring CB represents a divalent carborane group C 2 B 10 H 10 - represented by any one of the formula (a), the formula (b), and the formula (c), and when a plurality of rings CB are present in a molecule, the rings may be identical to or different from each other; R represents hydrogen, a substituted or unsubstituted aliphatic hydrocarbon group having 1 to 12 carbon atoms, a substituted or unsubstituted aromatic hydrocarbon group having 6 to 50 carbon atoms, or a substituted or unsubstituted aromatic heterocyclic group having 3 to 50 carbon atoms, and a plurality of R's may be identical to or different from each other; A represents a direct bond, an Si d group, a substituted or unsubstituted aromatic hydrocarbon group having 6 to 50 carbon atoms, or a substituted or unsubstituted aromatic heterocyclic group having 3 to 50 carbon atoms, provided that A does not represent a direct bond except when p+m represents 2, and A represents a p+m-valent group when A represents a group except a direct bond, R of the Si d group has the same meaning as that of the R, and d represents an integer represented by 4-(p+m); and p represents an integer of from 0 to 3, m represents an integer of from 1 to 4, n represents an integer of from 0 to 3, and p+m represents an integer of from 1 to 4. a ring CB represents a divalent carborane group C 2 B 10 H 10 - represented by any one of the formula (a), the formula (b), and the formula (c), and when a plurality of rings CB are present in a molecule, the rings may be identical to or different from each other; R represents hydrogen, a substituted or unsubstituted aliphatic hydrocarbon group having 1 to 12 carbon atoms, a substituted or unsubstituted aromatic hydrocarbon group having 6 to 50 carbon atoms, or a substituted or unsubstituted aromatic heterocyclic group having 3 to 50 carbon atoms, and a plurality of R's may be identical to or different from each other; A represents a direct bond, an Si d group, a substituted or unsubstituted aromatic hydrocarbon group having 6 to 50 carbon atoms, or a substituted or unsubstituted aromatic heterocyclic group having 3 to 50 carbon atoms, provided that A does not represent a direct bond except when p+m represents 2, and A represents a p+m-valent group when A represents a group except a direct bond, R of the Si d group has the same meaning as that of the R, and d represents an integer represented by 4-(p+m); and p represents an integer of from 0 to 3, m represents an integer of from 1 to 4, n represents an integer of from 0 to 3, and p+m represents an integer of from 1 to 4.
A viscous thixotropic haemostatic gel composition for use in promoting haemostasis at a site of blood loss in a patient in need thereof wherein the viscous thixotropic haemostatic gel composition comprises an ionic precipitating agent selected from ferric chloride and an iron sulphate, inclusive of ferric subsulphate, a fatty alcohol, an alcohol phosphate diester and one of an alkoxyether phosphate or a monoester phosphate of an alkoxylated fatty alcohol; optionally wherein the composition further comprises a local anaesthetic; and optionally wherein the blood loss is caused by: A. a surgical procedure selected from the group consisting of a curettage, colposcopy and biopsy or a dental procedure or uterine or haemorrhoidal bleeding; or B. a physical trauma. A. a surgical procedure selected from the group consisting of a curettage, colposcopy and biopsy or a dental procedure or uterine or haemorrhoidal bleeding; or B. a physical trauma.
A vaccine for use in protecting an otitis prone child against otitis media by immunization, wherein the otitis media is caused by Nontypeable Haemophilus influenzae (NTHi) infection and the vaccine comprises NTHi outer membrane protein 6.
An injection system for delivering a pharmaceutical fluid to a patient via an injection procedure performed in connection with an imaging procedure, the imaging procedure being performed with an imaging system comprising a scanner having at least one x-ray tube, wherein the injection system comprises a parameter generator programmed for determining parameters of at least a first phase of the injection procedure wherein at least one of the parameters is determined on the basis of a voltage to be applied to the at least one x-ray tube of the imaging system during the imaging procedure, characterized in that: the parameter generator is programmed to determine at least one of a volume of the pharmaceutical fluid to be injected during at least the first phase and a flow rate of the pharmaceutical fluid to be injected during at least the first phase on the basis of the voltage to be applied to the at least one x-ray tube during the imaging procedure, and wherein the parameter generator is programmed to determine the volume of the pharmaceutical fluid to be injected during at least the first phase by adjusting a volume parameter of a baseline injection protocol, such that the injection system is programmed to deliver the pharmaceutical fluid to the patient during at least the first phase of the injection procedure according to the determination of the volume of the pharmaceutical fluid to be injected during at least the first phase. the parameter generator is programmed to determine at least one of a volume of the pharmaceutical fluid to be injected during at least the first phase and a flow rate of the pharmaceutical fluid to be injected during at least the first phase on the basis of the voltage to be applied to the at least one x-ray tube during the imaging procedure, and wherein the parameter generator is programmed to determine the volume of the pharmaceutical fluid to be injected during at least the first phase by adjusting a volume parameter of a baseline injection protocol, such that the injection system is programmed to deliver the pharmaceutical fluid to the patient during at least the first phase of the injection procedure according to the determination of the volume of the pharmaceutical fluid to be injected during at least the first phase.
A process for producing a jellyfish collagen hydrogel comprising jellyfish collagen fibrils, said process comprising: a. mixing: i. a solution of purified jellyfish collagen; and ii. an aqueous neutralisation buffer; and b. incubating the mixture for a sufficient amount of time to enable collagen fibrils to form, wherein a cross-linking agent is either added during the mixing step (a) or to the collagen fibrils obtained from step (b). a. mixing: i. a solution of purified jellyfish collagen; and ii. an aqueous neutralisation buffer; and i. a solution of purified jellyfish collagen; and ii. an aqueous neutralisation buffer; and b. incubating the mixture for a sufficient amount of time to enable collagen fibrils to form,
A method for producing a pressed board, wherein before a press cake is pressed using pressing means (4, 5), an outer release agent is applied, in order to prevent the press cake from adhering to the pressing means (4, 5), wherein 10 - 60 weight percent of at least one synthetic resin is added to the outer release agent in order to form a coating on the pressed board in the form of a film, the cohesion of which is greater than the adhesion thereof to metal, up to 60 weight percent of a starch solution is added to the release agent, characterized in that 10 - 60 weight percent of polyurethane and/or at least one polyurethane copolymer are added to the outer release agent.
A power reduction system (20-1, 20-n) comprising: an input configured to receive power from a power source; a plurality of outputs configured to provide output power to a plurality of loads; a plurality of switches coupled to the input and the plurality of outputs; a network interface configured to receive a power status message from a network; a controller coupled to the switches and the network interface and configured to control the switches to selectively couple/decouple the input to/from the outputs in response to the power status message; characterized in comprising an energy consumption module coupled to the input and configured to determine a reduced energy consumption measure based on A) energy provided by the input during a time period during which the controller decouples the input from at least one of the outputs and B) a baseline energy consumption estimate for the time period, wherein the network interface is coupled to the energy consumption module and is further configured to transmit the reduced energy consumption measure toward a remote device connected to the network. an input configured to receive power from a power source; a plurality of outputs configured to provide output power to a plurality of loads; a plurality of switches coupled to the input and the plurality of outputs; a network interface configured to receive a power status message from a network; a controller coupled to the switches and the network interface and configured to control the switches to selectively couple/decouple the input to/from the outputs in response to the power status message; characterized in comprising an energy consumption module coupled to the input and configured to determine a reduced energy consumption measure based on A) energy provided by the input during a time period during which the controller decouples the input from at least one of the outputs and B) a baseline energy consumption estimate for the time period, wherein the network interface is coupled to the energy consumption module and is further configured to transmit the reduced energy consumption measure toward a remote device connected to the network.
A retinal implant comprising at least one first internal functional unit arranged for being disposed inside the vitreous cavity of an eye and at least one third external functional unit arranged for being disposed outside the eye, characterized by at least one second external functional unit arranged for being disposed outside the vitreous cavity of the eye and inside the eye orbit and by a signal path (5, 6, 7) for signal and data transmission between the first and the second as well as between the second and the third functional units, wherein the signal path between the first and second functional units has a wireless inductive connection (6, 7).
A urological device (800, 810, 830, 860, 900, 910, 920) comprising:- - a urological valve (803, 812, 861, 901); - a valve support stem (801, 813, 863, 902) for location in the urethra of a patient, wherein the valve support stem (801, 813, 863, 902) comprises a generally tubular support for extending at least partially through the urethra; and wherein the urological device comprises a bladder retainer (802, 811, 862, 903) for locating the valve in the bladder, the bladder retainer comprising a flare (811, 862, 903) extending radially outwardly of the support stem (801, 813, 863, 902); characterized in that, the valve (803, 812, 861, 901) having a normally closed configuration to prevent flow from the bladder and an open configuration for fluid flow through the valve, the valve being automatically movable from the closed configuration to the open configuration in response to a pre-set hydrodynamic pressure applied for a pre-set time, and in that the urological valve (803, 812, 861, 901) is adapted for location in the bladder of a patient and is located at a bladder end of the support (801, 813, 863, 902). - a urological valve (803, 812, 861, 901); - a valve support stem (801, 813, 863, 902) for location in the urethra of a patient, wherein the urological device comprises a bladder retainer (802, 811, 862, 903) for locating the valve in the bladder, the bladder retainer comprising a flare (811, 862, 903) extending radially outwardly of the support stem (801, 813, 863, 902); characterized in that, the valve (803, 812, 861, 901) having a normally closed configuration to prevent flow from the bladder and an open configuration for fluid flow through the valve, the valve being automatically movable from the closed configuration to the open configuration in response to a pre-set hydrodynamic pressure applied for a pre-set time, and in that the urological valve (803, 812, 861, 901) is adapted for location in the bladder of a patient and is located at a bladder end of the support (801, 813, 863, 902).